Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)

Phase 3

Recruiting

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Atezolizumab
Drug: Bevacizumab
Other: Placebo
Drug: Tiragolumab

First Posted Date: 2023-06-15

Last Posted Date: 2024-11-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 650

Registration Number: NCT05904886

Locations: 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸
UCLA MEDICAL CENTER; Alhambra, Alhambra, California, United States
🇺🇸
UCSF Fresno at Community Cancer Institute, Clovis, California, United States

and more 234 locations

HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Atezolizumab
Drug: Bevacizumab
Procedure: HAIC with FOLFOX

First Posted Date: 2023-06-02

Last Posted Date: 2023-06-02

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 40

Registration Number: NCT05886465

Locations: 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Solid Tumor
Non-small Cell Lung Cancer
Gastric Cancer
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: RO7496353
Drug: Capecitabine
Drug: Atezolizumab
Drug: Nab-paclitaxel
Drug: S-1
Drug: Gemcitabine
Drug: Nivolumab
Drug: Oxaliplatin

First Posted Date: 2023-05-19

Last Posted Date: 2024-12-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 102

Registration Number: NCT05867121

Locations: 🇺🇸
UCLA University of California Los Angeles, Los Angeles, California, United States
🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

and more 26 locations

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Phase 3

Recruiting

Conditions: Cancer

Interventions: Drug: Tiragolumab
Drug: Ipatasertib
Drug: Atezolizumab

First Posted Date: 2023-05-17

Last Posted Date: 2024-12-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 60

Registration Number: NCT05862285

Locations: 🇨🇷
Clinica CIMCA, San José, Costa Rica
🇨🇳
Chang Gung Memorial Hospital - Linkou, Taoyuan, Taiwan
🇲🇽
Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico

and more 19 locations

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

Phase 2

Not yet recruiting

Conditions: Lung Cancer
Metastatic NSCLC - Non-Small Cell Lung Cancer
Advanced NSCLC
NSCLC Stage IV

Interventions: Drug: Cabozantinib
Drug: Atezolizumab

First Posted Date: 2023-05-15

Last Posted Date: 2024-05-08

Lead Sponsor: Jun Zhang, MD, PhD

Target Recruit Count: 40

Registration Number: NCT05859217

Locations: 🇺🇸
The University of Kansas Cancer Center - Westwood, Kansas City, Kansas, United States
🇺🇸
The University of Kansas Cancer Center - Indian Creek, Overland Park, Kansas, United States
🇺🇸
The University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States

and more 1 locations

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Phase 2

Recruiting

Conditions: SCLC

Interventions: Drug: PM8002
Drug: Platinum
Drug: Atezolizumab
Drug: Etoposide

First Posted Date: 2023-05-06

Last Posted Date: 2024-12-11

Lead Sponsor: Biotheus Inc.

Target Recruit Count: 445

Registration Number: NCT05844150

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

and more 14 locations

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Phase 2

Active, not recruiting

Conditions: Clinical Stage II Gastric Cancer AJCC v8
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastric Cancer AJCC v8
Clinical Stage I Gastric Cancer AJCC v8
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Biological: Atezolizumab
Procedure: Biospecimen Collection
Drug: Capecitabine
Procedure: Computed Tomography
Drug: Docetaxel
Procedure: Echocardiography
Drug: Fluorouracil
Drug: Leucovorin Calcium
Procedure: Lymphadenectomy
Procedure: Magnetic Resonance Imaging
Drug: Oxaliplatin
Procedure: Positron Emission Tomography
Procedure: Surgical Procedure

First Posted Date: 2023-05-01

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 240

Registration Number: NCT05836584

Locations: 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
Kaiser Permanente Dublin, Dublin, California, United States

and more 133 locations